Valuation

REPLReplimune Group Inc.

StockNasdaqUnited StatesHealth careEU retail: available

+23.1% today · +53.7% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 8% of the instruments we score

Quality: among the weakest; priced higher than most peers. No dividend.

Replimune Group Inc. (REPL) valuation against sector peers: P/B 7.4, free-cash-flow yield −16.1%, P/S 168.1.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricREPLSector medianvs median
P/E—30.6 · n=152—
P/B7.44.0 · n=30586% above
P/S168.14.4 · n=2973,694% above
EV/EBIT—25.8 · n=139—
Free-cash-flow yield−16.1%1.4% · n=2871,237% below
Dividend yield0.00%0.00% · n=358—
Return on equity−115.8%−3.7% · n=306—
Return on invested capital—0.4% · n=275—
Gross margin—61.7% · n=202—
Net debt / EBITDA—1.31 · n=146—

Value factor: 2 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co45.435.8—1.5%0.6%7/10
JNJJohnson & Johnson40.58.0—3.2%1.9%8/10
ABBVAbbVie80.6—33.83.6%3.0%5/10
UNHUnitedHealth25.93.519.16.5%2.2%9/10
MRKMerck109.68.3—4.6%2.4%9/10
TMOThermo Fisher Scientific37.44.936.72.8%0.3%10/10
AMGNAmgen27.920.925.24.2%2.2%7/10
GILDGILEAD—16.7—6.6%2.0%5/10
ABTAbbott28.43.426.84.1%3.0%6/10
PFEPfizer38.72.0—6.5%7.3%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 28 Oct 2026